UC WAR. CALL 03/25 GS71/ DE000HD43L20 /
2024-05-16 9:00:59 AM | Chg.0.0000 | Bid9:25:49 AM | Ask9:25:49 AM | Underlying | Strike price | Expiration date | Option type |
---|---|---|---|---|---|---|---|
0.6300EUR | 0.00% | 0.5900 Bid Size: 25,000 |
0.6000 Ask Size: 25,000 |
GSK PLC LS-,3125 | 21.00 - | 2025-03-19 | Call |
GlobeNewswire
05-15
Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update
GlobeNewswire
05-13
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Developme...
GlobeNewswire
05-10
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
GlobeNewswire
05-09
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-09
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) ...
GlobeNewswire
05-09
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sag...
GlobeNewswire
05-09
Wave Life Sciences Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-09
Wave Life Sciences Announces Appointment of Dr. Erik Ingelsson as Chief Scientific Officer
GlobeNewswire
05-09
Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results
GlobeNewswire
05-08
SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
05-08
Alector Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
05-08
Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wed...
GlobeNewswire
05-08
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in ...
GlobeNewswire
05-07
BioVersys Announces Expansion of Strategic Collaboration With GSK and Extension of Its Series C Roun...
GlobeNewswire
05-01
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
04-30
SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the Euro...
GlobeNewswire
04-30
Wave Life Sciences Announces Approval of First Clinical Trial Application for RestorAATion-2 Trial o...
GlobeNewswire
04-25
Nucleome Therapeutics appoints Dr John Davis as Non-Executive Director of the Board and establishes ...
GlobeNewswire
04-23
Wave Life Sciences Announces Continued Momentum in GSK Collaboration and Advancements in siRNA and R...